Characteristics of patients
| . | MPN (n = 74) . | PV (n = 29) . | ET JAK2-WT (n = 27) . | ET JAK2-V617F (n = 14) . | RT (n = 16) . | HD (n = 21) . |
|---|---|---|---|---|---|---|
| History of thrombosis | 31% (23/74) | 34.5% (10/29) | 11% (3/27) | 64% (9/14) | 0 | 0 |
| Splenomegaly | 33% (22/66) | 26% (7/27) | 22% (6/27) | 36% (5/14) | 0 | ND |
| WBC at diagnosis, 109/L | 8.7 (6.95-10.35) | 9.2 (7.8-10.9) | 7.6 (7.1-9.7) | 8.2 (6.9-12.2) | 10.8 (9.5-14.9) | 6.5 (5.9-8.9) |
| ANC at diagnosis, 109/L | 5.55 (4.25-7.37) | 5.95 (4.55-8.67) | 5.1 (3.97-6.5) | 4.9 (3.4-8) | ND | ND |
| HB at diagnosis, g/dL | 14 (13-15.9) | 16.9 (14.8-19.1) | 13 (12.6-13.5) | 14.2 (13.3-14.2) | 10.6 (9.6-11.5) | 13.8 (12.6-15) |
| Hematocrit at diagnosis, % | 42.25 (39.3-50.12) | 50.5 (44.7-61.4) | 39.3 (38.7-41) | 41.7 (40-42.1) | 32.8 (29.8.1-35.3) | 41.5 (38-43.2) |
| Platelets at diagnosis, 109/L | 599.5 (400-766) | 448 (322-626) | 739 (619-918) | 682 (481-807) | 652 (595-702) | 237 (225-277) |
| % JAK2-V617F | 30 (15-40) | 35 (17-45) | 0 | 17 (11-29) | ND | ND |
| Epo, U/L | 8.8 (7.15-12.9) | 6.4 (5.12-8.15) | 11.6 (8.8-13.7) | 11 (8.6-12.9) | ND | ND |
| . | MPN (n = 74) . | PV (n = 29) . | ET JAK2-WT (n = 27) . | ET JAK2-V617F (n = 14) . | RT (n = 16) . | HD (n = 21) . |
|---|---|---|---|---|---|---|
| History of thrombosis | 31% (23/74) | 34.5% (10/29) | 11% (3/27) | 64% (9/14) | 0 | 0 |
| Splenomegaly | 33% (22/66) | 26% (7/27) | 22% (6/27) | 36% (5/14) | 0 | ND |
| WBC at diagnosis, 109/L | 8.7 (6.95-10.35) | 9.2 (7.8-10.9) | 7.6 (7.1-9.7) | 8.2 (6.9-12.2) | 10.8 (9.5-14.9) | 6.5 (5.9-8.9) |
| ANC at diagnosis, 109/L | 5.55 (4.25-7.37) | 5.95 (4.55-8.67) | 5.1 (3.97-6.5) | 4.9 (3.4-8) | ND | ND |
| HB at diagnosis, g/dL | 14 (13-15.9) | 16.9 (14.8-19.1) | 13 (12.6-13.5) | 14.2 (13.3-14.2) | 10.6 (9.6-11.5) | 13.8 (12.6-15) |
| Hematocrit at diagnosis, % | 42.25 (39.3-50.12) | 50.5 (44.7-61.4) | 39.3 (38.7-41) | 41.7 (40-42.1) | 32.8 (29.8.1-35.3) | 41.5 (38-43.2) |
| Platelets at diagnosis, 109/L | 599.5 (400-766) | 448 (322-626) | 739 (619-918) | 682 (481-807) | 652 (595-702) | 237 (225-277) |
| % JAK2-V617F | 30 (15-40) | 35 (17-45) | 0 | 17 (11-29) | ND | ND |
| Epo, U/L | 8.8 (7.15-12.9) | 6.4 (5.12-8.15) | 11.6 (8.8-13.7) | 11 (8.6-12.9) | ND | ND |
MPN, myeloproliferative neoplasm; PV, polycythemia vera; ET, essential thrombocythemia; RT, reactive thrombocytosis; HD, healthy donors; ND, not done; MPN includes 29 PV, 41 ET, and 4 PMF patients (the latter are not detailed in this table). Statistics are given as percentage for categorical values, or as median (first - third quartile) for continuous variables; WBC, white blood cell count; ANC, absolute neutrophil count; Hb, hemoglobin; % JAK2-V617F, percentage of JAK2-V617F allele in granulocytes of JAK2-V617F patients; Epo, serum erythropoietin level.